News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Robert H. Dworkin, Ph.D. Joins Scientific Board at MMS Holdings, Inc.


6/15/2011 10:11:35 AM

Canton, MI (June 15, 2011) - MMS Holdings is pleased to announce the addition of Robert H. Dworkin, Ph.D. to its scientific board. With over thirty years of experience, Dr. Dworkin is a proven leader in the pharmaceutical industry. While serving on the board at MMS, Dr. Dworkin is the Director of the Analgesic Clinical Trial Innovations, Opportunities, and Networks (ACTION) public-private partnership with the US Food and Drug Administration (FDA); Co-chair of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT); a member of the US Centers for Disease Control and Prevention (CDC) Zoster Working Group; and a Special Government Employee of the FDA Center for Drug Evaluation and Research. He is a member of the Editorial Boards of Pain, Journal of Pain, Clinical Journal of Pain, and Current Pain and Headache Reports, and has previously served as a consultant to and member of the FDA Anesthetic and Life Support Drugs Advisory Committee and as a member of the CDC Measles, Mumps, Rubella, and Varicella Working Group. In 2005, he received the American Pain Society’s Wilbert E. Fordyce Clinical Investigator Award, which “recognizes individual excellence and achievements in clinical pain scholarship and is presented to a pain professional whose total career research achievements have contributed significantly to clinical practice.”

With funding from IMMPACT, the primary focus of Dr. Dworkin’s current research involves methodologic aspects of analgesic clinical trials, especially identifying factors that might increase the assay sensitivity of a trial to detect differences between an active and a control or comparison treatment. In addition, Dr. Dworkin has for many years conducted studies of risk factors for the development of different types of chronic pain, which have been funded by the National Institutes of Health, the Department of Defense, and various pharmaceutical companies. One of the major results of this research has been that patients with greater acute pain are more likely to develop chronic pain, which suggests that attenuating acute pain might prevent chronic pain.

Bob is currently Professor of Anesthesiology, Neurology, Oncology, and Psychiatry, Professor in the Center for Human Experimental Therapeutics, and Director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry.

At MMS, Dr. Dworkin provides consulting and advisory services in strategy and implementation of drug development activities including regulatory affairs. Rob also serves MMS as a subject matter expert in the chronic pain therapeutic area including neuropathic pain, low back pain, cancer pain, fibromyalgia, and osteoarthritis.

About MMS Holdings Inc.

MMS Holdings Inc. is based in Canton, MI and is a highly experienced pharmaceutical service organization that is focused on quality deliverables in the areas of Clinical Programming, Biostatistics, Medical /Regulatory Writing and Comprehensive Pharmacovigilance. Commitment to Quality deliverables with robust submission experience sets MMS apart from traditional service providers. MMS Holdings Inc. is ISO-9001 certified for all services and maintains detailed quality metrics for every project. For more information visit: http://www.mmsholdings.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES